OKT 3: nursing considerations for use in acute renal transplant rejection

The development of monoclonal antibodies represents a significant biomedical advancement. The increasing use of muromonab-CD3 (Orthoclone OKT 3) for the treatment of acute rejection requires that the health care professional has a thorough understanding of its effects and regimen for proper and safe administration. This article reviews monoclonal antibody production and administration with an emphasis placed on the nursing implications associated with the use of OKT 3 in acute renal transplant rejection.